About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome

NCT02037672·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Medical Centre Ljubljana

Age

18–55

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

18 years old to menopause
polycystic ovary syndrome (NICHD criteria)
BMI of 30 kg/m² or higher

You may not be if

depression
type 1 or type 2 diabetes mellitus
history of carcinoma
Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
significant cardiovascular, kidney or hepatic disease
the use of medications other than metformin known or suspected to affect reproductive or metabolic functions
the use of statins, within 90 days prior to study entry

The record

StatusCompleted

PhasePhase 4

Taking part36

StartedSep 2013

UpdatedJan 22, 2014

Conditions

Where1

University Medical Center Ljubljana
Ljubljana, Slovenia

Clareo Health | PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome